GLOBAL BARRETT’S ESOPHAGUS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Global Barrett’s esophagus market is estimated to be valued at USD 5.05 Bn in 2024 and is expected to reach USD 7.20 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

Barrett's esophagus is a condition where the lining of the esophagus is damaged due to chronic acid reflux. It is a serious complication of gastroesophageal reflux disease (GERD) where the lining of the esophagus is replaced by the abnormal tissue similar to the lining of the intestine. This change in the cells of the esophagus can increase the chances of developing esophageal adenocarcinoma, a type of esophageal cancer. Barrett's esophagus usually does not cause symptoms but can be diagnosed by esophagogastroduodenoscopy (EGD) along with biopsy. The key predisposing factor is chronic GERD where stomach acid damages the esophagus over many years. Other risk factors include obesity, smoking, and male gender. The condition needs to be closely monitored as it is a precursor to esophageal cancer. Treatment involves lifestyle modifications and medication to control acid reflux. In some cases, radiofrequency ablation or endoscopic mucosal resection may be recommended to remove dysplastic tissues.

Market Dynamics:

Global Barrett’s esophagus market growth is driven by increasing prevalence of gastroesophageal reflux disease (GERD) and obesity rates worldwide. Chronic and untreated GERD are major risk factors for Barrett’s esophagus. According to the National Institute of Diabetes and Digestive and Kidney Diseases Report published in 2020, approximately 60 million Americans experience heartburn at least once a month. Obesity is another important factor predisposing to GERD due to excess pressure on the abdomen. The market also stands to benefit from routine screening practices for esophageal cancer. However, the market growth can be restrained by the asymptomatic nature of Barrett’s esophagus leading to underdiagnoses in some cases. Lack of approved drugs for the treatment and high cost of management procedures also challenges the market to some extent. Nevertheless, ongoing research on novel diagnostic biomarkers and therapeutic strategies present lucrative opportunities in the long run.

Key Features of the Study:

• This report provides an in-depth analysis of the global Barrett’s esophagus market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Barrett’s esophagus market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include AstraZeneca, Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Sanofi, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, AbbVie Inc., Ferring Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global Barrett’s esophagus market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Barrett’s esophagus market

Detailed Segmentation:

• By Drug Class:
• • Proton Pump Inhibitors (PPIs)
  • H2 Receptor Antagonists
  • Mucosal Protective Agents
  • Others (Endoscopic Therapy Drugs, etc.)
• By Distribution Channel:
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region: 
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
• • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • AbbVie Inc.
  • Ferring Pharmaceuticals
  • Otsuka Pharmaceutical Co., Ltd.
  • Taiho Pharmaceutical Co., Ltd.
  • Ono Pharmaceutical Co., Ltd.